Biological CSF markers of Alzheimer's disease (Q37217953)

19 August 2017

1 reference

title

Biological CSF markers of Alzheimer's disease (English)

1 reference

19 August 2017

0 references

1

Henrik Zetterberg

1 reference

19 August 2017

2

Kaj Blennow

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn

19 August 2017

published in

1 reference

19 August 2017

volume

89

1 reference

19 August 2017

page(s)

261-268

1 reference

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal Fluid Tau Levels in Neurodegenerative Diseases with Distinct Tau-Related Pathology

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

CSF markers for incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

The use of proteomics in biomarker discovery in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Amyloid plaque core protein in Alzheimer disease and Down syndrome

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Glia and their cytokines in progression of neurodegeneration

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Neurofilament protein levels in CSF are increased in dementia.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Alzheimer's disease: genes, proteins, and therapy

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Alzheimer's disease is a synaptic failure

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Biochemical evidence for the long-tail form (A beta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Characterization of beta-amyloid peptide from human cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Brain ubiquitin is markedly elevated in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

Cerebrospinal fluid markers for prediction of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016/S0072-9752(07)01224-9

7 January 2021

10.1016/S0072-9752(07)01224-9

Identifiers

DOI

1 reference

19 August 2017

1 reference